Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting PSMD6
- Development stage
- Preclinical
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA targeting PSMD6 is an experimental RNA interference (RNAi) therapeutic approach designed to treat multiple myeloma by silencing the expression of the PSMD6 gene. PSMD6 encodes a non-ATPase subunit of the 19S regulatory particle of the 26S proteasome, which is essential for protein homeostasis. In multiple myeloma, which is highly dependent on proteasome function, knockdown of PSMD6 leads to the accumulation of K48-linked polyubiquitinated proteins, induction of endoplasmic reticulum (ER) stress, G0-G1 cell cycle arrest, and apoptosis. This strategy aims to overcome resistance to traditional 20S proteasome inhibitors by targeting the regulatory particle upstream. Research is primarily being conducted at the Dana-Farber Cancer Institute.
- Other names
- PSMD6 siRNAPSMD-6 siRNAPSMD 6 siRNAsiPSMD6siPSMD-6siPSMD 6
02
Targets
PSMD6 (26S proteasome non-ATPase regulatory subunit 6)
Beyond the preview
Go deeper on siRNA targeting PSMD6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting PSMD6.